ARCT
NASDAQ · Biotechnology
Arcturus Therapeutics Holdin
$8.23
+0.37 (+4.71%)
Open$7.86
Previous Close$7.86
Day High$8.48
Day Low$7.71
52W High$24.17
52W Low$5.50
Volume—
Avg Volume602.8K
Market Cap222.41M
P/E Ratio—
EPS$-3.31
SectorBiotechnology
Analyst Ratings
Strong Buy
18 analysts
Price Target
+220.9% upside
Current
$8.23
$8.23
Target
$26.41
$26.41
$16.23
$26.41 avg
$33.18
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 89.91M | 122.21M | 31.39M |
| Net Income | -72,098,820 | -88,200,269 | -5,088,256 |
| Profit Margin | -80.2% | -76.2% | -16.2% |
| EBITDA | -80,265,878 | -103,646,301 | -7,015,778 |
| Free Cash Flow | — | — | -5,929,972 |
| Rev Growth | -26.4% | -26.4% | +5.3% |
| Debt/Equity | — | — | 0.28 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $258.92 | +3.43% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $425.28 | +1.41% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $143.44 | +3.25% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $528.19 | +2.45% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $810.24 | +0.53% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.61 | +1.79% | 37.6 | 30.39B |